6

A regulatory perspective on in vitro diagnostics

Year:
2006
Language:
english
File:
PDF, 678 KB
english, 2006
7

The FDA Critical Path Initiative and Its Influence on New Drug Development*

Year:
2008
Language:
english
File:
PDF, 232 KB
english, 2008
8

Role of Postmarketing Surveillance in Contemporary Medicine *

Year:
2011
Language:
english
File:
PDF, 1.02 MB
english, 2011
14

Biosimilars: The US Regulatory Framework

Year:
2017
Language:
english
File:
PDF, 362 KB
english, 2017
16

Expediting drug development for serious illness: Trade-offs between patient access and certainty

Year:
2018
Language:
english
File:
PDF, 79 KB
english, 2018
22

Cytomatrix synthesis in MDCK epithelial cells

Year:
1990
Language:
english
File:
PDF, 1.23 MB
english, 1990
23

Interference of sucrose with the fluorometric assay of tryptophan

Year:
1976
Language:
english
File:
PDF, 367 KB
english, 1976
27

Risk Management: Issues for Outcomes Research

Year:
2003
Language:
english
File:
PDF, 58 KB
english, 2003
29

Remote sensing for land management and planning

Year:
1983
Language:
english
File:
PDF, 3.19 MB
english, 1983
32

Empowering microarrays in the regulatory setting

Year:
2006
Language:
english
File:
PDF, 56 KB
english, 2006
37

Transporters in drug development: advancing on the Critical Path

Year:
2010
Language:
english
File:
PDF, 161 KB
english, 2010
40

Janet Woodcock discusses the FDA and the drug development process

Year:
2004
Language:
english
File:
PDF, 248 KB
english, 2004
47

Principles of Clinical Pharmacology || Physiological and Laboratory Markers of Drug Effect

Year:
2012
Language:
english
File:
PDF, 491 KB
english, 2012
49

FDA's Critical Path Initiative

Year:
2007
Language:
english
File:
PDF, 68 KB
english, 2007
50

FDA's Critical Path Initiative

Year:
2007
Language:
english
File:
PDF, 69 KB
english, 2007